Brief: Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Viracta Therapeutics

08/01/2023 18:05

Jan 8 (Reuters) - Viracta Therapeutics Inc  VIRX.O :
    * VIRACTA THERAPEUTICS ANNOUNCES FIRST CLINICAL RESPONSE IN
EPSTEIN-BARR VIRUS-POSITIVE (EBV+) SOLID TUMOR SETTING AND
OUTLINES KEY 2023 CLINICAL OBJECTIVES
    * VIRACTA THERAPEUTICS- CASH, CASH EQUIVALENTS, AND
INVESTMENTS OF
OVER $90 MILLION AT YEAR-END 2022 PROVIDE ANTICIPATED RUNWAY
INTO LATE 2024
    * VIRACTA THERAPEUTICS-ANTICIPATE PROVIDING  UPDATE ON
NAVAL-1’S
FIRST LYMPHOMA SUBTYPE THAT MAY ADVANCE FROM STAGE 1 TO STAGE 2
IN FIRST HALF OF 2023

Source text for Eikon:  ID:nGNX50Ltsj 
Further company coverage:  VIRX.O 
 ((Reuters.briefs@thomsonreuters.com;))